TABLE 1.
Characteristics of study participantsa
| Participant ID | Age (yr) | Gender | ART regimen | Duration of viral load <50 copies/ml (mo) | Time to initiation of ART (mo) | IUPM |
|---|---|---|---|---|---|---|
| OM5001 | 43 | M | DTG/FDC/TDF | >100 | 14 | 10.5 |
| B004 | 63 | F | FTC/TDF/EFV | >20 | – | 2.8 |
| OM5334 | 32 | M | EVG/FTC/COBI/TAF/RPV | 32 | 2 | 1.7 |
| OM5148 | 47 | M | NVP/KVX | 105 | 57 | 1.0 |
a
The age, gender, ART regimen (ABC, abacavir; COBI, cobicistat; DTG, dolutegravir; EFV, efavirenz; EVG, elvitegravir; FTC, emtricitabine; KVX, abacavir/3TC; NVP, nevirapine; RAL, raltegravir; RPV, rilpivirine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate), time viremia was suppressed, and time from diagnosis to initiation of ART are listed for each donor. In addition, the latent replication-competent HIV reservoir in the PBMC of each donor was quantified by QVOA and is reported as infectious units/million CD4+ T cells (IUPM). –, unknown.